Table 1.
Serious adverse events (SAE) among 37 patients treated by Rituximab for AIDs
| Age | Gender | Disease | Drugs at the time of AE | Co-morbidity | Adverse event | Time of AE | B cell % | Evolution | Response to RTX |
|---|---|---|---|---|---|---|---|---|---|
| 51 | F | MPG-cryoglobulinaemic vasculitis | Prednisone 60 mg | HCV infection | Cutaneous necrosis over a catheter port | M2 | 0 | Resolved | Yes |
| Interferon-ribavirin | |||||||||
| 47 | M | MPG-cryoglobulinaemia-HCV | Ciclosporin 100 mg | Renal engraftment | Staphylococcal cellulitis | M12 | 3 | Resolved | Yes |
| MMF 2 g | CMV reactivation | ||||||||
| Prednisone 5 mg | |||||||||
| 56 | F | MPG-VHC | Prednisone 5 mg | Renal engraftment | Staphylococcus aureus | M5 | 1 | Resolved | No |
| MMF 1000 mg | Pseudomonas aeruginosa | ||||||||
| Tacrolimus 3 mg | pneumopathy | ||||||||
| Disseminated HSV2 | |||||||||
| 40 | M | TTP | Prednisone 60 mg | Urinary catheter | Escherichia coli septicaemia | M2 | 0 | Resolved | No |
| 52 | M | WG | Prednisone 60 mg | Renal dialysis | Haemorrhagic collapse | M1 | 0 | Resolved | Yes |
| CPM 100 mg day−1 | |||||||||
| 53 | M | WG | Prednisone 60 mg | Renal dialysis | Pneumocystosis | M2 | 0 | Resolved Resolved Resolved Resolved | Yes |
| Digestive and lung haemorrhage | Severe lymphopenia neutropenia anemia | Resolved | |||||||
| Resolved | |||||||||
| Resolved | |||||||||
| 57 | F | AIHA | Prednisone 15 mg | Pleuro-pneumopathy | M10 | ND | Resolved | No | |
| 85 | H | ITP | Prednisone 60 mg | Waldenström's gammaglobulinaemia | Bacterial pneumopathy | M2 | ND | Resolved | Yes |
| 70 | F | Pure red cell aplasia | Prednisone 30 mg | Chronic malnutrition | Shock and epidermolysis | M1 | ND | Died | No |
| 73 | F | AIHA | Prednisone 1 mg kg−1 day−1 | Uncontrolled haemolysis | M5 | ND | Died | No | |
| IV CPM | |||||||||
| 72 | M | AIHA | Methylprednisolone 60–120 mg day−1 | Undiagnosed AIL-like T-lymphoma | Septic choc | M2 | 0 | Died | No |
| Pneumocystosis | |||||||||
| Uncontrolled haemolysis | |||||||||
| 50 | M | Wegener's | I.v. methylprednisolone, i.v. CPM | Uncontrolled cerebral vasculitis | D3 | ND | Died | NE | |
| 80 | M | Acquired anti-Willebrand | IV-Ig (inefficacy) | End-stage renal disease | Undefined | M3 | ND | Died | No |
| 77 | F | ITP | Prednisone 2 mg kg−1 | Splenectomy | Cerebral bleeding | D7 | ND | Died | No |
| IV-Ig |
One Wegener's patient had SAE in 2004 and in 2005 after re-treatment. AE, adverse event; AIHA, autoimmune haemolytic anemia; CPM, cyclophosphamide; D, day; HCV, hepatitis C virus; HSV, herpes simplex virus; ITP, immune thrombocytopenic purpura; IV-Ig, intravenous immunoglobulins; M, month; MMF, mycophenolate mophetil; MPG, membranoproliferative glomerulonephritis; ND, not done; NE, not evaluable; RTX, rituximab; TTP, thrombotic thrombocytopenic purpura; WG, Wegener's granulomatosis.